Vol. 6 (10) pp. 41-53 DOI: 10.21474/IJAR01/7783

THE CARDIO-PROTECTIVE "PARAOXONASE-1" AS A VALUABLE PROMISING TOOL IN DIAGNOSIS AND/OR ASSESSMENT OF CARDIOVASCULAR RISK IN TYPE 2 DIABETES.

, , and
  • Faculty of Pharmacy, Helwan University, Department of Biochemistry and Molecular Biology, Cairo, Egypt.
  • NationalInstitute for diabetes and Endocrinology, Department of Biochemistry, Cairo, Egypt.
  • NationalInstitute for diabetes and Endocrinology, Department of Internal medicine, Cairo, Egypt.
  • NationalInstitute for diabetes and Endocrinology, Department of Clinical & chemical pathology, Cairo, Egypt.
9 Downloads 101 Views
Crossref

Download Full Paper (PDF)

Abstract

Background: Type 2 Diabetes Mellitus \\\"T2D\\\"remains frequently undiagnosed for many years; as the hyperglycemia is often not severe enough to provoke noticeable symptoms. Thus, such patients are at increased risk of developing macrovascular and microvascular events. Diabetic cardiovascular \\\"CVD\\\" complications are one of the most leading causes of death worldwide. Prevention of long-term chronic complications has become one of the main goals of modern treatment in T2D. However, new tools are still needed for early detection or even prediction of CVD risk to facilitate decreasing morbidity and mortality rates associated with T2D. Objectives:In this study, authors aimed to afford access to information that may allow early detection &/or prediction of macrovascular complications in Egyptian patients with T2D. Subjects and Methods:The study included200 clinically diagnosed T2D patients (subdivided according to presence of CVD complication). In addition, 60 healthy controls were selected with comparable socioeconomic, age, body mass index, and sex distribution. Inclusion and exclusion criteria were applied. Glycemic control indices, lipid profile, Paraoxonase-1, MCP-1, ICAM-1, VCAM 1, and Lp (a) were measured. Results were statistically analyzed. Results: Serum levels of Paraoxonase-1 (↓),MCP-1 (↑), ICAM-1 (↑), VCAM 1 (↑), and Lp (a) (↑) were altered significantly in both diabetic cohorts compared to healthy controls. Also, Paraoxonase-1 (↓↓), MCP-1 (↑↑), ICAM-1 (↑↑), VCAM 1 (↑↑) levels showed significant alteration in T2D patients with CVD compared to those without complication. Additionally, with respect to prediction of CVD risk, results predict that Paraoxonase-1 has higher and better diagnostic accuracy index as indicated by ROC analysis. Conclusion: Paraoxonase-1 is a sensitive biomarker in T2D with anti-atherogenic cardio-protective properties; its circulating levels may be a valuable future tool for early diagnosis and/or assessment of CVD risk associated with T2D.

Keywords

How to Cite This Article

Ahmed M.A. Akabawy, Heba I. Hamed, Wafaa S. Hegab and Naglaa F. Mohamed. (2018); THE CARDIO-PROTECTIVE "PARAOXONASE-1" AS A VALUABLE PROMISING TOOL IN DIAGNOSIS AND/OR ASSESSMENT OF CARDIOVASCULAR RISK IN TYPE 2 DIABETES., International Journal of Advanced Research (IJAR), 6 (10), 41-53, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/7783

Corresponding Author

Ahmed Mohammed Abd El-Mohsin Mahmoud Akabawy
Faculty of Pharmacy - Helwan University

Article Analytics

References

  1. Albers J.J., Koschinsky M.L., Marcovina S.M., 2007. Evidence mounts for a role of the kidney in lipoprotein (a) catabolism. Kidney International, 71(10), 961-2.
  2. Allain C.C., Poon L.S., Chan C.S., Richmond W., Pu F.C., 1974. Enzymatic determination of total serum cholesterol. Clinical Chemistry, 20, 470-475.
  3. Arakelyan A., Petrkova J., Hermanova Z., Boyajyan A., Lukl J., Petrek M., 2005. Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators of Inflammation, 175?9.
  4. ArgravesM., Kozarsky K.F., Fallon J.T., Harpel P.C., Strickland D.K., 1997. The atherogenic lipoprotein Lp (a) is internalized and degraded in a process mediated by the VLDL receptor. The Journal of Clinical Investigation, 100(9), 2170-81.
  5. Barham D., Trinder P., 1972. An important colour reagent for the determination of blood glucose by the oxidase system. Analyst, 97, 142 -145.
  6. Basta G., Schmidt A.M., De Caterina R., 2004. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovascular Research, 63,582?592.
  7. Bhattacharyya T. S. J., Nicholls E. J., Topol R., Zhang X., Yang D., Schmitt X., Fu M., Shao D. M., Brennan S. G., Ellis., et al., 2008. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. The?Journal of the American Medical Association, 299, 1265?1276.
  8. Bo S., Ciccone G., Gancia R., Rosato R., Grassi G., Merletti F., et al.,2006. Mortality within the first 10 years of the disease in type 2 diabetic patients. Nutrition Metabolism Cardiovascular Diseases, 16, 8?12.
  9. Boemi M., Leviev I., Sirolla C., Pieri C., Marra M., James R.W., 2001. Serum paraoxonase is reduced in Type 1 diabetic patients compared to non-diabetic, first-degree relatives: influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis, 155,229-35.
  10. Brownlee, M., 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 4,813?820.
  11. Carlos T.M., Harlan J.M., 1994. Leukocyte-endothelial adhesion molecules. Blood, 84, 2068-101.
  12. Chan B.M., Elices M.J., Murphy E., Hemler M.E., 1992. Adhesion to vascular cell adhesion molecule 1 and fibronectin. Comparison of alpha 4 beta 1 (VLA-4) and alpha 4 beta 7 on the human B cell line JY. The Journal of Biological Chemistry, 267, 8366-70.
  13. Costa L. G., Cole T. B., Furlong C. E., 2005. Paraoxonase (PON1): from toxicology to cardiovascular medicine. ActaBiomedica, 76 (Suppl. 2), 50?57.
  14. Cybulsky M.I., Gimbrone M.A., 1991. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science, 251,788?91.
  15. Danesh J., Collins R., Peto R., 2000. Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation, vol.102, no.10, pp.1082?1108.
  16. de Lemos J.A., Morrow D.A., Blazing M.A.,Jarolim P., Wiviott S.D., Sabatine M.S., Califf R.M., Braunwald E.,2007. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. Journal of the American College of Cardiology, 50, 2117?2124.
  17. de Lemos J.A., Morrow D.A., Sabatine M.S., Murphy S.A., Gibson C.M., Antman E.M., McCabe C.H., Cannon C.P., Braunwald E., 2003. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation, 107,690?695.
  18. Deakin S. P., James R. W., 2004. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clinical Science, (Lond.). 107,435?447.
  19. Elices M.J., Osborn L., Takada Y., et al., 1990. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell, 60,577-84.
  20. Finley P.R., Schifman R.B., Williams R.J., Lichhti D.A., 1978. Cholesterol in high- density lipoprotein: use of Mg 2+/dextran sulphate in its enzymatic measurement. Clinical Chemistry, 24, 931- 933.
  21. Ford E.S., 1999. Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care,22, 1971?7.
  22. Friedewald W.T., Levy R.I., Fredrickson D.S., 1972.Estimation of the concentration of low- densitylipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18,499-502.
  23. Gaidukov L., Tawfik D. S., 2007. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. The Journal of Lipid Research, 48, 1637?1646.
  24. Galen F.X., 2002. Cell adhesion molecules in hypertension: endothelial markers of vascular injury and predictors of target organ damage? Journal of Hypertension, 20,813-6.
  25. Garlichs C.D., John S., Schmeisser A., Eskafi S., Stumpf C., Karl M., Goppelt-StruebeM.,Schmieder R., Daniel W.G., 2001. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation, 104, 2395?2400.
  26. Gearing A.J., Newman W., 1993. Circulating adhesion molecules in disease.Immunol Today, 14,506?12.
  27. Giuliano D., Ceriello A., Paolisso G., 1996.Oxidative stress and diabetic vascular complications. Diabetes Care, 19,257?267.
  28. Gokulakrishnan K., Deepa R., Mohan V., 2008. Association of high sensitivity C - reactive protein [hsCRP] and tumour necrosis factor-α [TNF-α] with carotid intimal medial thickness in subjects with different grades of glucose intolerance?The Chennai Urban Rural Epidemiology Study (CURES-31). Clinical Biochemistry,41,480-5.
  29. Goswami B., Tayal D., Gupta N., Mallika V., 2009. Paraoxonase: a multifaceted biomolecule. ClinicaChimicaActa, 410, 1-12.
  30. Gross E.R., Ladisia J.F., Weihrauch D., Olson L.E., KressT.T., Hettrick D.A., et al.,Reactive oxygen species modulate coronary walls hear stress and endothelial function during hyperglycemia. American Journal of Physiology Heart and Circulatory Physiology, 28, 1552-9.
  31. Hanaa L., Noreddine G., Hassan T., Anass K., Loubna E.R., Benyounes R., et al., 2008. Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. Journal of Clinical Lipidology, 2, 43-50.
  32. Hofer S. E., Bennetts B., Chan A. K., Holloway B., Karschimkus C., Jenkins A. J., Silink M., Donaghue K. C., 2006. Association between PON 1 polymorphisms, PON activity and diabetes complications. Journal of Diabetes Complications, 20,322?328.
  33. Holmes D. T., Schick B. A., Humphries K. H., Frohlich J., 2005. Lipoprotein (a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clinical Chemistry, vol.51, no.11, pp.2067?2073.
  34. Horvit P.K., Garber A.J., 1998. Diabetes and atherosclerosis: mechanisms and management. Endocrinology Practice, 4,112-119.
  35. Inadera H., Egashira K., Takemoto M., OuchiY., Matsushima K., 1999. Increase of circulating levels of monocyte chemoattractant protein-1 in aging. Journal of Interferon and Cytokine Research, 19, 1179?1182.
  36. James, R. W., 2006. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clinical Chemistry and Laboratory Medicine, 44, 1052?1059.
  37. Kalmar T., Seres I., Balogh Z., Kaplar M., Winkler G., Paragh G., 2005. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes Metabolism, 31,574-80.
  38. Karabina S.A., Lehner A.N., Frank E., Parthasarathy S., Santanam N., 2005. Oxidative inactivation of paraoxonase implications in diabetes mellitus and atherosclerosis. BiochimicaetBiophysicaActa, 1725, 213-21.
  39. Kim J., Montagnani M., Koh K.K., Quon M.J., 2006. Reciprocal relationship between insulin resistance and endothelial dysfunction. Circulation, 113, 1888-904.
  40. Koschinsky M.L., Marcovina S.M., 1997. Lipoprotein (a): structural implications for pathophysiology. Int J Clin Lab Res; 27(1):14-23.
  41. Kuusisto J., Mykkanen L., Pyorala K., Laakso M., 1994. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke, 25, 1157-1164.
  42. Laakso, M., 2010. Cardiovascular disease in type 2 diabetes from population to man to mechanisms. Diabetes Care, vol. 33, no. 2, pp.442?449.
  43. Lambadiari V., Kadoglou N.P., Stasinos V., Maratou E., Antoniadis A., Kolokathis F., et al., 2014.Serum levels of retinol-binding protein-4 are associated with the presence and severity of coronary artery disease. Cardiovascular Diabetology, 13,121.
  44. Lehto S., Ronnemaa T., Haffner S.M., Pyorala K., Kallio V., Laakso M., 1997.Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes, 46, 1354-1359.
  45. Lehto S., Ronnemaa T., Pyorala K., Laakso M., 1996. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke, 27, 63-68.
  46. Li G., Lu W.H., Ai R., Yang J.H., Chen F., Tang Z.Z., 2014. The relationship between serum hypoxia-inducible factor 1α and coronary artery calcification in asymptomatic type 2 diabetic patients. Cardiovascular Diabetology, 13, 52.
  47. Libby P., Ridker P.M., Maseri A., 2002. Inflammation and atherosclerosis. Circulation, 105, 1135-43.
  48. Mackness B., Durrington P.N., Abuashia B., Boulton A.J., Mackness M.I., 2000. Low paraoxonase activity in Type II diabetes complicated by retinopathy. Clinical Science, 98,355-63.
  49. Mackness M., Mackness B., 2004. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radical Biology and Medicine, 37, 1317?1323.
  50. Mansson M., Kalies I., Bergstrometal G., 2014. Lp (a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo. Nature, Scientific Reports, vol.4, article5318.
  51. Marcovina S.M., Hegele R.A., Koschinsky M.L., 1999. Lipoprotein (a) and coronary heart disease risk.Current Cardiology Reports, vol.1, no.2, pp.105?111.
  52. Maritim C., Sanders R., Watkins J.B., 2003. Effects of lipoic acid on biomarkers of oxidative stress in streptozotocin induced diabetic rats. The Journal of Nutritional Biochemistry, 14,288-94.
  53. Marta T., Gl?ria L., Mariano S., Jaume M., 2004. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Revista Espanola De Cardiologia, 57,557-69.
  54. Mastorikou M., Mackness B., Liu Y., Mackness M., 2008. Glycation of paraoxonase-1 inhibits ????????????itsactivity and impairs the ability of high-density lipoprotein to metabolize membranelipid hydroperoxides. Diabetic Medicine, 25, 1049-55.
  55. McGowan M.W., Artiss J.D., StrandberrghD.R., Zak B.A., 1983. Peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clinical Chemistry, 29, 538- 542.
  56. Min KyongMoon., 2016. Lipoprotein (a): a not-so-well-known risk factor for the development of cardiovascular disease in patients with type 2 diabetes mellitus. The Korean Journal of Internal Medicine, 31, 1061-1063.
  57. Newman P.J., Berndt M.C., Gorski J., White G.C. 2nd, Lyman S., Paddock C., Muller W.A., 1990. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science, 247, 1219?22.
  58. Ockenhouse C.F., Tegoshi T., Maeno Y., et al., 1992. Human vascular endothelial cell adhesion receptors for Plasmodium falciparum-infected erythrocytes: roles for endothelial leukocyte adhesion molecule 1 and vascular cell adhesion molecule 1.The Journal of Experimental Medicine, 176, 1183-9.
  59. Okeoghene O. A., Azenabor A., 2011. Glycaemic indices and non-traditional biochemical cardiovascular disease markers in a diabetic population in Nigeria. Journal of the College of Physicians and Surgeons Pakistan, vol. 21, no. 8, pp. 455?459.
  60. Osborn L., Hession C., Tizard R., et al., 1989. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell, 59, 1203-11.
  61. Ozougwu J. C., Obimba K. C., Belonwu C. D., Unakalamba C. B., 2013. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. Journal of Physiology and Pathophysiology, vol.4, no.4, pp.46?57.
  62. Paneni F., Beckman J.A., Creager M.A., Cosentino F., 2013. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical theraphy: part I. European Heart Journal, 34, 2436?43.
  63. Papayianni A., Alexopoulos E., Giamalis P., Gionanlis L., Belechri A.M., Koukoudis P., Memmos D., 2002. Circulating levels of ICAM-1, VCAM-1 and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidemia and vascular events. Nephrology Dialysis Transplantion, 17,435?441.
  64. Parissis J.T., Venetsanou K.F., Kalantzi M.V., Mentzikof D.D., Karas S.M., 2000 Serum profile of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. American Journal of Cardiology, 85,777?779.
  65. Piemonti L., Calori G., Lattuada G., Mercalli A., Ragogna F., Garancini M.P., et al., 2009 Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and non-diabetic individuals. Diabetes Care, 32, 2105?10.
  66. Piemonti L., Colori G., Mercalli A., et al., 2003.Fasting plasma leptin, tumor necrosis factor-α receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care, 26, 2883-9.
  67. Pyorala K., Laakso M., Uusitupa M., 1987. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metabolism Review, 3,463?524.
  68. Qi Q., Workalemahu T., Zhang C., Hu F.B., Qi L., 2012. Genetic variants, plasma lipoprotein (a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. European Heart Journal, 33(3), 325-34.
  69. Reape T.J., Groot P.H., 1999. Chemokines and atherosclerosis. Atherosclerosis, 147, 213?225.
  70. Ridker P.M., Libby P., 2012. Risk markers for atherothrombotic disease. In: Bonow RO, Mann DL, Zipes DP, Libby P, editors. Braunwald?sheart disease: a textbook of cardiovascular medicine. 9th ed.Philadelphia, PA: Elsevier Saunders, p. 927-8.
  71. Ridker, P.M., 2001. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet, 358,946-8.
  72. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., TawfikD.S.,et al., 2006. The catalytic histidine dyad of high density lipoprotein associated serum paraoxonase-1 (PON1) is essential for PON1 mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. The journal of Biological Chemistry, 281, 7657-65.
  73. Ross R., 1999. Atherosclerosis: an inflammatory disease. The New England Journal of Medicine,340,115-26.
  74. Rubio A.F., Vargas H., Vargas G., Escalante B.A., 2007. Correlation between circulating adhesion molecules levels and albuminuria in type 2 diabetic normotensive patients. Medical Science Monitor, 13,349-52.
  75. Ruderman N.B., Gupta S., Sussman I., 1992. Hyperglycemia, diabetes, and vascular disease. New York: Oxford University Press, 3-20.
  76. , DiweshChawla., ManushiSiddarth., BasuDevBanerjee.,SriVenkataMadhu., Ashok Kumar Tripathi.,2013. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications.Clinical Biochemistry, 46, 109?114.
  77. Shih D. M., Xia Y. R., Wang X. P., Miller E., Castellani L. W., Subbanagounder G., Cheroutre H., Faull K. F., Berliner J. A., Witztum J. L., et al., 2000. Combined serum paraoxonase knockout/ apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. The Journal of Biological Chemistry, 275, 17527?17535.
  78. Shiwaku K., Anuurad E., Enkhmaa B., KitajimaK ., Yamane Y., 2004. Body-mass index for Asian populations for policy and intervention strategies. Lancet, 363, 157-63.
  79. Staunton D.E., Marlin S.D., Stratowa C., Dustin M.L., Springer T.A., 1988. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell, 52,925?33.
  80. Van der Hoek Y.Y., Wittekoek M.E., Beisiegel U., Kastelein J.J., Koschinsky M.L., 1993. The apolipoprotein (a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Human Molecular Genetics, 2(4), 361-6.
  81. Van Himbergen T.M., van Tits L.J.H., Roest M., Stalenhoef A.F.H., 2006. The story of PON1: how an organophosphate hydrolysing enzyme is becoming a player in cardiovascular medicine. The Netherlands Journal of Medicine , 64, 34-8.
  82. Vasiliades, J., 1976. Reaction of alkaline sodium picrate with creatinine: Kinetics and mechanism of the mono-creatinine picric acid complex. Clinical Chemistry, 22(10), 1664-1671.
  83. Vlassara H., Palace M.R., 2002. Diabetes and advanced glycation end products. Journal of Internal Medicine, 251, 87?101.
  84. Witkowska A.M., Borawska M.H., 2004. Soluble intercellular adhesion molecule-1(sICAM-1): an overview. European Cytokine Network, 15, 91?8.
  85. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M., 2003.Glycation, inflammation and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circulation Research, 93, 1159?1169.
  86. Zeljkovic N., Bogavac-Stanojevic Z., Jelic-Ivanovic V., Spasojevic-Kalimanovska J., Vekic.,Spasic S., 2009. Combined effects of small apolipoprotein (a) isoforms and small, dense LDL on coronary artery disease risk. Arch Med Res.40(1): 29-35.

Similar Articles

Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.